Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VYGR vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Captures Overall Composite Edge (36.8 SELL vs 47.5 HOLD), While VYGR Leads 3–2 on Growth & Valuation Pillars

BOLD Overall Winner 6-Pillar Tally: VYGR 3 – 2 BOLD (1 Tie) Matrix Metrics: VYGR 5 – 4 BOLD

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Voyager Therapeutics, Inc. (VYGR) on higher Unified Composite conviction (36.8/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while VYGR wins 3–2 across the 6-pillar growth and valuation breakdown. VYGR trades at $1.53 (8.4x Forward P/E, -436.2% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. -70.0% YoY).
  • Technical & Structure Timing Caution: VYGR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VYGR vs BOLD
VYGR NASDAQ
Voyager Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.53
-4.97% 1D
Market Cap $100.2M
TTM Revenue $25M
Forward P/E 8.4x
Beta / 30D Vol 1.49β · 86% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 49.0 Fund 59.0 Flow 64.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.9%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.74 · SMA50: $2.21
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (VYGR 3 – 2 BOLD)

Columns: Metric · VYGR · BOLD
1. Valuation Multiples VYGR
Forward P/E 8.4x N/M
Trailing P/E 8.4x N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x N/M
2. Growth & Scale VYGR
Revenue Growth (YoY) -70.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M N/A
Market Cap $100.2M $56.2M
3. Profitability & Quality BOLD
Gross Margin N/A N/A
Operating Margin -436.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -58.9% -64.6%
4. Balance Sheet & Cash Flow VYGR
Cash Generation (TTM) -$110M -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage $18M Net Cash $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 130.1% (31st %ile) N/A (N/A)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VYGR (5) vs BOLD (4)
Institutional Metric VYGR BOLD Criterion Row Edge
Market Capitalization
Scale
$100.2M $56.2M Larger Scale VYGR
Trailing P/E Ratio
Valuation
8.4x N/M Lower Multiple VYGR
Forward P/E Ratio
Valuation
8.4x N/M Lower Multiple VYGR
Revenue Growth (YoY)
Growth
-70.0% +0.0% Higher Growth BOLD
Operating Margin (TTM)
Profitability
-436.2% 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-58.9% -64.6% Higher ROE VYGR
52-Week Range Position
Momentum
1% ($1–$5) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
1.49β · 86% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite VYGR
Trailing 12M Revenue (USD)
Operating Scale
$25M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($18M Net Cash) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +12.82 pp
VYGR: -17.74% · BOLD: -4.92%
3M Horizon BOLD +33.9 pp
VYGR: -55.52% · BOLD: -21.62%
6M Horizon BOLD +120.85 pp
VYGR: -59.74% · BOLD: +61.11%
1Y Horizon BOLD +164.96 pp
VYGR: -63.22% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VYGR vs BOLD. Trailing 12-month operating profitability (VYGR -436.2% vs BOLD 0.0%) and valuation multiples (VYGR 8.4x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VYGR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25M
Gross MarginN/A
Op. Margin-436.2%
ROE / Fwd P/E-58.9% · 8.4x
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VYGR BREAKDOWN
178d in phase · OBV DISTRIBUTION
Current IV 130.1%
IV Percentile 31st %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VYGR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VYGR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $100.2M market capitalization and -436.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VYGR vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Voyager Therapeutics, Inc. (VYGR) on higher Unified Composite conviction (36.8/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while VYGR wins 3–2 across the 6-pillar growth and valuation breakdown. VYGR trades at $1.53 (8.4x Forward P/E, -436.2% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. -70.0% YoY). Technical & Structure Timing Caution: VYGR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VYGR leads the Growth & Scale pillar: VYGR posts -70.0% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -436.2% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VYGR generates $25M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, VYGR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

VYGR screens cheaper on headline valuation multiples. VYGR trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VYGR (-58.9% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VYGR carries 130.1% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.49β · 86% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.